D
Kazia Therapeutics Limited KZIA
$13.25 $3.1931.71% NASDAQ
Recommendation
Prev Close
$10.06
Volume
260,306
Avg Vol (90D)
521,841
Market Cap
$18.46M
Dividend & Yield
--
52-Week Range
$2.86 - $26.00
P/E (TTM)
--
EPS (TTM)
-$6,484.10
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development
12/2/2025 - TipRanks Financial Blog
What's Going On With Cancer Firm Kazia Therapeutics
12/2/2025 - Benzinga
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
12/2/2025 - GuruFocus
Kazia Therapeutics trading resumes
12/2/2025 - The Fly
Kazia Therapeutics trading halted, volatility trading pause
12/2/2025 - TipRanks Financial Blog
Kazia Therapeutics trading halted, volatility trading pause
12/2/2025 - The Fly
Kazia Therapeutics (KZIA) Secures $50M Through Private Placement
12/2/2025 - GuruFocus
Kazia Therapeutics announces pricing of $50M private placement
12/2/2025 - The Fly
Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities
12/2/2025 - PR Newswire
Nuclear Power Surge, $10M Buyback, and a $1.9B SEO Bombshell
11/19/2025 - Globe Newswire
What Sparked Kazia Therapeutics' Over 51% After-Hours Surge?
11/19/2025 - Benzinga
Kazia Therapeutics (KZIA) Reports Promising Response in Breast Cancer Treatment
11/18/2025 - GuruFocus
Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline
11/18/2025 - TipRanks Financial Blog
Kazia reports results from patient with stage IV TNBC treated with pembrolizumab
11/18/2025 - TipRanks Financial Blog
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
11/18/2025 - PR Newswire
Kazia Therapeutics Delays 20-F Filing
10/31/2025 - TipRanks Financial Blog
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and ...
10/27/2025 - GuruFocus
Kazia Therapeutics to request FDA Type C meeting
10/27/2025 - The Fly
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
10/27/2025 - PR Newswire
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 ...
10/7/2025 - GuruFocus
Kazia Therapeutics signs collaboration and in-licensing agreement for PD-L1
10/7/2025 - The Fly
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
10/7/2025 - PR Newswire
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of ...
10/2/2025 - GuruFocus
Kazia Therapeutics price target raised by $5 at Maxim, here's why
10/2/2025 - The Fly
Kazia Therapeutics (KZIA) Achieves Significant Tumor Reduction in Trial
10/2/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$1.16M
EBITDA (TTM)
-$8.30M
EBIT (TTM)
-$9.26M
Net Income (TTM)
-$13.41M
Balance Sheet
Total Assets (Q)
$3.97M
Total Debt (Q)
$259.60K
Total Liabilities (Q)
$9.42M
Book Value Per Share (Q)
-$1.68K
Cash Flow
Cash from Operations (TTM)
-$8.64M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$10.39M
Net Change in Cash (TTM)
$1.74M
Filings
Filing Date
Friday, November 7, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Jun 8 and 12 (est)
Price History
Loading...
Beta
1.83
7-Day Total Return
58.68%
30-Day Total Return
88.49%
60-Day Total Return
64.60%
90-Day Total Return
54.61%
Year to Date Total Return
51.86%
1-Year Total Return
-46.36%
2-Year Total Return
-40.82%
3-Year Total Return
-58.26%
5-Year Total Return
-97.37%
52-week Low
Apr 17, 2025 - $2.86
52-week High
Dec 03, 2024 - $26.00
Valuation
Market Cap
$18.46M - Nano Cap
Enterprise Value
$15.87M
Price/Sales (TTM)
0.02
Price/Book (Q)
-0.01
Dividends and Shares
Shares Outstanding
0.00
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kaziatherapeutics.com
Phone Number
61 2 9472 4101
Address
Three International Towers
Level 24 - 300 Barangaroo Avenue
Sydney, NSW 2000
Country
Australia
Year Founded
1994
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small... more
NASDAQ 12/03/2025 4:00PM Eastern Quotes delayed